TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
NCT04923529
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
28
Enrollment
OTHER
Sponsor class
Conditions
Pancreas Cancer
Interventions
DRUG:
TAS 102
Sponsor
The University of Hong Kong
Collaborators
[object Object]